HDAC6 and cancer: The exposed conflicting data of ARID1A role in endometrial carcinogenesis and the fact that ARID1A directly suppresses HDCA6 provide evidence that HDAC6 may be a promising therapeutic target in ARID1A‐mutated cancers.